This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms
Sandra E. Kurtin, PhDc, ANP-C, AOCN®
Arizona Cancer Center
Get an overview of the diagnostic criteria and key clinical trials for Philadelphia chromosome–negative classical myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. Learn about the role of the JAK-STAT signaling pathway, as well as strategies for optimizing the selection and sequencing of treatments for patients with myeloproliferative neoplasms.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |